Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine

Entecavir (ETV) exhibits potent antiviral activity in patients chronically infected with wild-type or lamivudine (3TC)-resistant (3TC(r)) hepatitis B virus (HBV). Among the patients treated in phase II ETV clinical trials, two patients for whom previous therapies had failed exhibited virologic break...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antimicrob Agents Chemother
Hauptverfasser: Tenney, D. J., Levine, S. M., Rose, R. E., Walsh, A. W., Weinheimer, S. P., Discotto, L., Plym, M., Pokornowski, K., Yu, C. F., Angus, P., Ayres, A., Bartholomeusz, A., Sievert, W., Thompson, G., Warner, N., Locarnini, S., Colonno, R. J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Microbiology (ASM) 2004
Schlagworte:
Antiviral Agents
Online Zugang:https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC514758/
https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15328117/
https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.48.9.3498-3507.2004
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge